Hepatitis B virus receptors and molecular drug targets

Eloi R. Verrier, Ph.D.[1,2], **Che C. Colpitts, Ph.D.**[1,2], **Camille Sureau, Ph.D.**[3], **Thomas F. Baumert, MD**[1,2,4,*]

[1]Inserm, U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, 67000 Strasbourg, France

[2]Université de Strasbourg, 67000 Strasbourg, France

[3]INTS, Laboratoire de Virologie Moléculaire, 75015 Paris, France

[4]Institut Hospitalo-Universitaire, Pôle Hépato-digestif, Nouvel Hôpital Civil, 67000 Strasbourg, France

Abstract

Chronic Hepatitis B virus (HBV) infection is a leading cause of liver disease worldwide. Virus-induced diseases include cirrhosis, liver failure and hepatocellular carcinoma. Current therapeutic strategies may at best control infection without reaching cure. Complementary antiviral strategies aimed at viral cure, are therefore urgently needed. HBV entry is the first step of the infection cycle, which leads to the formation of cccDNA and the establishment of chronic infection. Viral entry may thus represent an attractive target for antiviral therapy. This review summarizes the molecular virology and cell biology of HBV entry, including the discovery and development of new HBV entry inhibitors, and discusses their potential in future treatment of HBV infection.

Keywords

Antiviral targets; host-targeting agents; liver; therapy; treatment

Introduction

With 250-350 million affected individuals, chronic hepatitis B virus (HBV) infection is a major public health problem. Chronic HBV infection can lead to advanced liver disease such as liver cirrhosis and liver failure (1–4). Furthermore, HBV infection is a leading cause of hepatocellular cellular carcinoma (HCC) worldwide (1–4). Despite a very efficient protective vaccine, HBV prevalence has only marginally declined. Current antiviral therapies involving pegylated type-I interferon (IFN) and nucleos(t)ide analogs (NUCs) may at best

*Corresponding author: Prof. Thomas F. Baumert, MD; Inserm U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Université de Strasbourg, 3 Rue Koeberlé, 67000 Strasbourg, France; Phone: +33 3 68 85 37 03, Fax: +33 3 68 85 37 24, thomas.baumert@unistra.fr.

control viral infection. There is no anti-HBV treatment available for efficient viral clearance in HBV carriers. HBV is a small, enveloped DNA virus of the *Hepadnaviridae* family, which exclusively infects human hepatocytes (4). The viral coat consists of three envelope proteins: small S (S), middle M (S + preS2 region) and large L (S + preS2 region + preS1 region) (5). Unique features of the HBV life cycle include a genome replication mechanism that uses a reverse transcription step (targeted by NUCs) to convert pregenomic RNA to genomic DNA, and the formation of a covalently closed circular DNA (cccDNA) in the nucleus of infected hepatocytes, the equivalent of proviral DNA in retrovirus-infected cells (6). The HBV cccDNA functions as a minichromosome in the nucleus of infected cells to serve as a template for transcription into viral mRNAs. Because it is responsible for viral persistence, HBV cccDNA is the target of choice for elimination of infection (6). HBV infection in humans may become more complex when patients are co-infected with the hepatitis delta virus (HDV). HDV is a subviral infectious agent, and an obligate satellite of HBV, which uses the HBV envelope proteins to assemble infectious particles and thereby propagate with the helper HBV. As for HBV, there is no curative treatment available (7), and chronic HBV/HDV co-infections lead to increased liver damage and HCC risk as compared to HBV mono-infections (8).

As current treatments may control, but not cure infection, new therapeutic strategies are needed, especially for treatment of chronic infections. Novel therapeutic approaches include host-targeting compounds that inhibit virus-host interactions as reviewed previously (9). As the first step of infection necessary for the formation of cccDNA and the establishment of chronic infection, viral entry represents an antiviral target in complement of current therapies (9–11). As HDV and HBV share the same envelope and entry pathway, targeting viral entry is of particular interest for the treatment of HBV/HDV co-infection. Here, we review the recent developments in our understanding of the HBV/HDV entry process, including the consequent new antiviral strategies.

HBV entry: the quest for a viral receptor

Although the HBV DNA replication cycle has been described in detail, molecular interactions between virus and host factors are not fully understood. One reason for this limitation has been the lack of robust cell culture infection systems for the study of the full life cycle. Viral entry can be observed in primary cultures of human hepatocytes (PHH) and *Tupaia belangeri* (PTH) hepatocytes (12, 13). One human hepatic progenitor cell line (HepaRG) has also demonstrated susceptibility to HBV infection following DMSO-mediated differentiation, and it has been used extensively in recent years for HBV and HDV in vitro infection assays (14). However, HBV/HDV susceptible systems are limited by a number of constraints: susceptibility to infection is highly dependent on culture conditions and, in the case of PHH, subject to donor-to-donor variability (4, 10, 15). Besides viral entry, all other steps of the HBV or HDV replication cycles have been studied for many years in permissive hepatoma cell lines, such as Huh7 and HepG2 cells (15–18). These cell lines, however, are not susceptible to HBV and HDV infection, limiting their use to genome replication, transcription, translation, viral assembly and release, but not viral entry (19). Consequently, the HBV receptor(s) have remained unknown for many years (20, 21). Only in late 2012 was a first bona-fide HBV receptor identified at the

basolateral membrane of differentiated human hepatocytes. Using PTH as target cells, and a labeled preS1 peptide as a bait to substitute for HBV envelope proteins, Yan et al. (22) identified the sodium taurocholate co-transporting polypeptide (NTCP), a bile-acid transporter mainly expressed at the basolateral membrane of hepatocytes (23) encoded by the *SLC10A1* gene, as an HBV-specific receptor (22, 24). In parallel, Ni et al. (24) had compared the transcriptomic pattern of differentiated (HBV susceptible) HepaRG cells to that of undifferentiated (not susceptible) HepaRG cells, and found that NTCP mRNA was expressed upon differentiation. Interestingly, the overexpression of human NTCP in permissive hepatoma cells such as Huh7 and HepG2 cells that lack endogenous expression of NTCP, conferred susceptibility to both HDV and HBV infection, thereby providing a cell culture model for the study of the entire HBV life cycle, including viral entry (22, 24).

Molecular biology of HBV entry

The interaction between HBV or HDV virions and hepatocytes begins with attachment to cell surface heparan sulfate proteoglycans (HSPGs) (25) (Figure 1). HSPGs are glycoproteins that play major roles in development and physiology (26), but they are also used for cellular attachment of numerous pathogens, including viruses (27). In the case of HBV, HSPG binding function was demonstrated by the ability of soluble heparin and other sulfated polysaccharides to impair infectivity of HDV and HBV virions (28, 29). Moreover, heparinase treatment of susceptible cells could inhibit HDV and HBV infection (28, 30). Using HepaRG cells, and a heparin-binding assay, Sureau and Salisse (30) reported that HSPGs bind to the antigenic loop of the HBV envelope protein S domain. HBV-HSPG interaction is one explanation to the highly specific tissue tropism of the virus, as viral glycoproteins recognize specific patterns of hepatic proteoglycans (including the degree of sulfation of HSPG) (25, 29). Taking advantage of NTCP-based cell culture systems and using a siRNA library targeting all members of HSPG families, Verrier et al. (31) recently demonstrated that glypican 5 (GPC5) was an attachment factor for HDV and HBV at the cell surface of hepatocytes. The involvement of GPC5 in HBV binding was confirmed by the inhibitory effect of an anti-GPC5 monoclonal antibody and by the ability of soluble recombinant GPC5 protein to neutralize HBV in vitro infection (31). GPC5 is a member of the glypican family, consisting of extracellular HSPGs bound at the cell surface through a glycosyl-phosphatidylinositol anchor (32). GPC5 carries five insertion sites (compared to three for GPC3, for instance) for highly sulfated glycosaminoglycan chains (33) and is expressed in PHH (31), possibly explaining the specific affinity of GPC5 for HBV virions. Since HSPG, and particularly GPC5, are involved in many cellular processes, including the control of cell division, growth regulation, FGF2- or Hedgehog signaling, HBV-HPSG interactions may also play a role in the pathogenesis of virus-induced liver disease (26, 33, 34). Further studies are needed for a comprehensive overview of HSPG-HBV interactions.

Following initial attachment to HSPGs, HBV and HDV virions bind to NTCP (Figure 1). Being a liver-specific transporter, NTCP is likely to play the major role in HBV liver tropism (35). In the liver, NTCP is responsible for the transport of conjugated bile salts, typically taurocholate (36). The preS1 domain at the surface of HBV virions directly interacts with the bile acid pocket site (aa 157–165) of NTCP (22, 24). The overlap between NTCP HBV receptor function and NTCP bile acid transporter function was confirmed by the ability

of NTCP S267F mutation to disrupt not only bile acid transport but also HDV and HBV infection in a cell culture model (37). Interestingly, two genetic studies showed that the S267F *SLC10A1* allele was associated with resistance to chronic HBV infection (38) and with decreased risk of cirrhosis and HCC in HBV carriers (39). However, the observation that S267F homozygous patients can still be infected by HBV (38, 39) demonstrates that this mutation does not totally suppress HBV entry *in vivo*, and suggests that other hepatic factor(s) can function as surrogate HBV receptors in absence of functional NTCP. A recent study identified another domain (aa 84–87) within NTCP that plays a crucial role in HBV entry, probably at a postbinding step (40). Interestingly, the overexpression of human NTCP in non-human cells is sufficient to confer susceptibility to HDV infection, suggesting that no additional human-specific factor is required for viral attachment, fusion and trafficking of the HDV genome to the cell nucleus (35, 40). However, hNTCP expression in mouse cells is not sufficient to confer susceptibility to HBV infection. Using fusion between hNTCP-overexpressing mouse cells and permissive non-susceptible HepG2 cells, Lempp et al. (41) recently suggested that the absence of HBV infection was due to a lack a host factor required for HBV replication. Following NTCP binding, HBV virions are thought to be internalized by endocytosis. Both clathrin- (42) and calveolin-dependent (43) processes have been proposed, but to date, the detailed mechanism of NTCP-mediated internalization remains unclear.

Currently, only a limited number of host proteins are known to be involved in HBV entry, and it is expected that the new NTCP-based infection models will allow the discovery of other entry factors. Given the relatively limited percentage of infected cells in this models, despite NTCP overexpression and high multiplicity of infection (22, 24, 31, 44), it is likely that additional factors indeed play an important role at viral entry.

HBV cell entry inhibitors

Entry inhibitors have emerged as attractive candidates for prevention and treatment of chronic viral infections (10, 35). Interestingly, in the context of hepatitis C virus (HCV), which also leads to chronic infection of the liver, an entry inhibitor used in monotherapy was shown to cure chronic infection in human liver chimeric mice (45). It is likely that hepatocyte turnover in the absence of *de novo* infection results in viral clearance (45). Furthermore, broadly neutralizing anti-envelope antibodies have been shown to control and eliminate persistent HCV infection in humanized mouse models (46). Indeed, by blocking reinfection and protecting uninfected hepatocytes from *de novo* infection, entry inhibitors may open perspectives for novel therapeutic approaches for HBV infection.

Neutralizing antibodies targeting viral envelope epitopes were the earliest entry inhibitors explored for HBV. Hepatitis B immunoglobulin (HBIG), a mixture of polyclonal antibodies targeting the HBV S protein, is currently used to prevent liver graft reinfection in HBV-positive patients (47). Monoclonal antibodies directed against the S protein (17.1.41 and 19.79.5) were shown to reduce HBV viral load and HBsAg levels in animal models (48) and in patients in a phase I clinical trial (49), but only for several days following treatment. Interestingly, a recent study demonstrated that the administration of a novel monoclonal anti-HBsAg antibody (E6F6) in a mouse model mimicking HBV infection not

only suppressed the levels of HBsAg and HBV DNA for several weeks but also facilitated the restoration of anti-HBV T-cell response (50, 51). Other monoclonal antibodies targeting the preS1 domain demonstrated marked anti-HBV activity *in vitro* (52) and in animal models (53) but have not been pursued in clinical trials.

Targeting host cell entry factors is a novel strategy that has been proposed in the context of HBV infection (10, 35). The attachment of HBV particles to the target hepatocyte relies on low-affinity interactions with HSPGs (25, 29). Small molecules that non-specifically interfere with HSPG binding therefore inhibit HBV infection. Highly sulfated compounds such as heparin (25) and suramin (54) inhibit HBV attachment by competing with cellular HSPGs for the binding sites in HBV surface proteins. GPC5 was recently identified as a HSPG possibly involved in this process (31). Indeed, a monoclonal antibody targeting GPC5 inhibited HBV infection in cell culture (31). Furthermore, synthetic anti-lipopolysaccharide peptides (SALPs) that bind to heparan sulfate moieties on the cell surface inhibit infection with a variety of enveloped viruses (55).

Since its discovery as a receptor for HBV/HDV, NTCP has been extensively explored as an antiviral target. The molecules targeting NTCP that exhibit antiviral functions against HBV are listed in Table 1. Myrcludex B, a myristoylated preS1-derived peptide, binds to NTCP and inhibits HBV infection by blocking binding of HBV to its receptor (10). PreS1-derived peptides inhibit HBV/HDV infection in vivo (56), and Myrcludex B prevents HBV spread in human liver chimeric mice (57). It is currently being evaluated in a phase IIa clinical trial (58). The first data suggest that Myrcludex B is well tolerated. The inhibition of HBV entry seems to be correlated with a decrease in both HBV DNA (> 1 log10) and HDV RNA, and with an improvement of hepatic parameters (ALT) (58). Other molecules also target NTCP and inhibit HBV infection. Cyclosporin A, a cyclic peptide, interferes with HBV entry as a result of its interactions with NTCP (44, 59). Ezetimibe, a small molecule inhibitor of NTCP-mediated bile acid uptake, also inhibits HBV/HDV entry by apparently similar mechanisms (60). Among several FDA-approved drugs with NTCP-inhibiting activity, irbesartan, a drug used for hypertension treatment, inhibited HBV infection in HepG2-NTCP cells as well as HDV infection in Huh7-NTCP cells (61, 62). Vanitaracin A, a tricyclic polyketide identified from a fungal secondary metabolite library, also interacts with NTCP to inhibit HBV/HDV infection (63). Ritonavir, an antiretroviral drug active against HIV infection, and having a putative inhibitory effect on NTCP metabolic function (64) inhibits HDV infection in Huh7-NTCP cells (62). A small screen of phytochemicals identified the green tea polyphenol epigallocatechin gallate as another HBV inhibitor, which possibly interferes with HBV uptake by altering the localization and stability of NTCP (65).

Conclusion and perspectives

Chronic HBV infection is a major public health problem worldwide. Since current anti-HBV treatments do not effectively cure infection (i.e., eliminate cccDNA), novel treatment approaches are needed. Entry inhibitors may contribute to cccDNA elimination through inhibition of cccDNA synthesis and prevention of entry in non-infected hepatocytes. However, as viral entry inhibitors including host-targeting compounds do not directly target cccDNA, they should be considered as a complementary antiviral strategy in combination

with other antiviral molecules, such as IFNs that can control cccDNA activity (9, 10, 35, 66–68). Recent progress in understanding the HBV entry process, particularly after the discovery of NTCP acting as a receptor, has lead to the identification of novel antiviral compounds for treatment of HBV and HDV infections. A key question will be whether entry inhibitors will help to cure HBV infection by preventing entry into cccDNA-free hepatocytes, while cccDNA-positive hepatocytes are eliminated by liver turnover. Further studies in state-of-the-art animal models and clinical trials are needed to address these questions, to ultimately establish the real place of entry inhibitors in the anti-HBV arsenal.

Funding

References

1. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol. 2005; 5: 215–229. [PubMed: 15738952]

2. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012; 142: 1264–1273. e1261 [PubMed: 22537432]

3. Thomas D, Zoulim F. New challenges in viral hepatitis. Gut. 2012; 61 (Suppl 1) i1–5. [PubMed: 22504915]

4. Zeisel MB, Lucifora J, Mason WS, Sureau C, Beck J, Levrero M, Kann M, Knolle PA, Benkirane M, Durantel D, Michel ML, et al. Towards an HBV cure: state-of-the-art and unresolved questions-report of the ANRS workshop on HBV cure. Gut. 2015; 64: 1314–1326. [PubMed: 25670809]

5. Urban S. Liver capsule: Entry and entry inhibition of hepatitis B virus and hepatitis delta virus into hepatocytes. Hepatology. 2016.

6. Nassal M. Hepatitis B virus cccDNA - viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut. 2015; 64: 1972–1984. [PubMed: 26048673]

7. Ciancio A, Rizzetto M. Chronic hepatitis D at a standstill: where do we go from here? Nat Rev Gastroenterol Hepatol. 2014; 11: 68–71. [PubMed: 24019153]

8. Wedemeyer H, Yurdaydin C, Dalekos GN, Erhardt A, Cakaloglu Y, Degertekin H, Gurel S, Zeuzem S, Zachou K, Bozkaya H, Koch A, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. 2011; 364: 322–331. [PubMed: 21268724]

9. Baumert TF, Verrier ER, Nassal M, Chung RT, Zeisel MB. Host-targeting agents for treatment of hepatitis B virus infection. Curr Opin Virol. 2015; 14: 41–46. [PubMed: 26262886]

10. Urban S, Bartenschlager R, Kubitz R, Zoulim F. Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology. 2014; 147: 48–64. [PubMed: 24768844]

11. Colpitts CC, Verrier ER, Baumert TF. Targeting viral entry for treatment of hepatitis B and C virus infections. ACS Infect Dis. 2015; 1: 420–427. [PubMed: 27617925]

12. Gripon P, Diot C, Theze N, Fourel I, Loreal O, Brechot C, Guguen-Guillouzo C. Hepatitis B virus infection of adult human hepatocytes cultured in the presence of dimethyl sulfoxide. J Virol. 1988; 62: 4136–4143. [PubMed: 3172341]

13. Walter E, Keist R, Niederost B, Pult I, Blum HE. Hepatitis B virus infection of tupaia hepatocytes in vitro and in vivo. Hepatology. 1996; 24: 1–5. [PubMed: 8707245]

14. Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I, Guyomard C, Lucas J, Trepo C, Guguen-Guillouzo C. Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci U S A. 2002; 99: 15655–15660. [PubMed: 12432097]

15. Dandri M, Lutgehetmann M, Petersen J. Experimental models and therapeutic approaches for HBV. Semin Immunopathol. 2013; 35: 7–21. [PubMed: 22898798]

16. Baumert TF, Rogers SA, Hasegawa K, Liang TJ. Two core promotor mutations identified in a hepatitis B virus strain associated with fulminant hepatitis result in enhanced viral replication. J Clin Invest. 1996; 98: 2268–2276. [PubMed: 8941643]

17. Sells MA, Chen ML, Acs G. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci U S A. 1987; 84: 1005–1009. [PubMed: 3029758]

18. Ladner SK, Otto MJ, Barker CS, Zaifert K, Wang GH, Guo JT, Seeger C, King RW. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob Agents Chemother. 1997; 41: 1715–1720. [PubMed: 9257747]

19. Glebe D, Urban S. Viral and cellular determinants involved in hepadnaviral entry. World J Gastroenterol. 2007; 13: 22–38. [PubMed: 17206752]

20. Engelke M, Mills K, Seitz S, Simon P, Gripon P, Schnolzer M, Urban S. Characterization of a hepatitis B and hepatitis delta virus receptor binding site. Hepatology. 2006; 43: 750–760. [PubMed: 16557545]

21. Gripon P, Cannie I, Urban S. Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J Virol. 2005; 79: 1613–1622. [PubMed: 15650187]

22. Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, Fu L, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife. 2012; 1 e00049 [PubMed: 23150796]

23. Claro da Silva T, Polli JE, Swaan PW. The solute carrier family 10 (SLC10): beyond bile acid transport. Mol Aspects Med. 2013; 34: 252–269. [PubMed: 23506869]

24. Ni Y, Lempp FA, Mehrle S, Nkongolo S, Kaufman C, Falth M, Stindt J, Koniger C, Nassal M, Kubitz R, Sultmann H, et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology. 2014; 146: 1070–1083. [PubMed: 24361467]

25. Schulze A, Gripon P, Urban S. Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. Hepatology. 2007; 46: 1759–1768. [PubMed: 18046710]

26. Bishop JR, Schuksz M, Esko JD. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature. 2007; 446: 1030–1037. [PubMed: 17460664]

27. Chen Y, Gotte M, Liu J, Park PW. Microbial subversion of heparan sulfate proteoglycans. Mol Cells. 2008; 26: 415–426. [PubMed: 18799929]

28. Lamas Longarela O, Schmidt TT, Schoneweis K, Romeo R, Wedemeyer H, Urban S, Schulze A. Proteoglycans act as cellular hepatitis delta virus attachment receptors. PLoS One. 2013; 8 e58340 [PubMed: 23505490]

29. Leistner CM, Gruen-Bernhard S, Glebe D. Role of glycosaminoglycans for binding and infection of hepatitis B virus. Cell Microbiol. 2008; 10: 122–133. [PubMed: 18086046]

30. Sureau C, Salisse J. A conformational heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis B virus a-determinant. Hepatology. 2013; 57: 985–994. [PubMed: 23161433]

31. Verrier ER, Colpitts CC, Bach C, Heydmann L, Weiss A, Renaud M, Durand SC, Habersetzer F, Durantel D, Abou-Jaoude G, Lopez Ledesma MM, et al. A targeted functional RNAi screen uncovers Glypican 5 as an entry factor for hepatitis B and D viruses. Hepatology. 2016; 63: 35–48. [PubMed: 26224662]

32. Filmus J, Capurro M, Rast J. Glypicans. Genome Biol. 2008; 9: 224. [PubMed: 18505598]

33. Filmus J, Capurro M. The role of glypicans in Hedgehog signaling. Matrix Biol. 2014; 35: 248–252. [PubMed: 24412155]

34. Li F, Shi W, Capurro M, Filmus J. Glypican-5 stimulates rhabdomyosarcoma cell proliferation by activating Hedgehog signaling. J Cell Biol. 2011; 192: 691–704. [PubMed: 21339334]

35. Baumert TF, Meredith L, Ni Y, Felmlee DJ, McKeating JA, Urban S. Entry of hepatitis B and C viruses - recent progress and future impact. Curr Opin Virol. 2014; 4C: 58–65.

36. Hagenbuch B, Meier PJ. Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter. J Clin Invest. 1994; 93: 1326–1331. [PubMed: 8132774]

37. Yan H, Peng B, Liu Y, Xu G, He W, Ren B, Jing Z, Sui J, Li W. Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide. J Virol. 2014; 88: 3273–3284. [PubMed: 24390325]

38. Peng L, Zhao Q, Li Q, Li M, Li C, Xu T, Jing X, Zhu X, Wang Y, Li F, Liu R, et al. The p.Ser267Phe variant in SLC10A1 is associated with resistance to chronic hepatitis B. Hepatology. 2015; 61: 1251–1260. [PubMed: 25418280]

39. Hu HH, Liu J, Lin YL, Luo WS, Chu YJ, Chang CL, Jen CL, Lee MH, Lu SN, Wang LY, You SL, et al. The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B. Gut. 2015.

40. Yan H, Peng B, He W, Zhong G, Qi Y, Ren B, Gao Z, Jing Z, Song M, Xu G, Sui J, et al. Molecular determinants of hepatitis B and D virus entry restriction in mouse sodium taurocholate cotransporting polypeptide. J Virol. 2013; 87: 7977–7991. [PubMed: 23678176]

41. Lempp FA, Mutz P, Lipps C, Wirth D, Bartenschlager R, Urban S. Evidence that hepatitis B virus replication in mouse cells is limited by the lack of a host cell dependency factor. J Hepatol. 2015.

42. Huang HC, Chen CC, Chang WC, Tao MH, Huang C. Entry of hepatitis B virus into immortalized human primary hepatocytes by clathrin-dependent endocytosis. J Virol. 2012; 86: 9443–9453. [PubMed: 22740403]

43. Macovei A, Radulescu C, Lazar C, Petrescu S, Durantel D, Dwek RA, Zitzmann N, Nichita NB. Hepatitis B virus requires intact caveolin-1 function for productive infection in HepaRG cells. J Virol. 2010; 84: 243–253. [PubMed: 19846513]

44. Watashi K, Sluder A, Daito T, Matsunaga S, Ryo A, Nagamori S, Iwamoto M, Nakajima S, Tsukuda S, Borroto-Esoda K, Sugiyama M, et al. Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP). Hepatology. 2014; 59: 1726–1737. [PubMed: 24375637]

45. Mailly L, Xiao F, Lupberger J, Wilson GK, Aubert P, Duong FHT, Calabrese D, Leboeuf C, Fofana I, Thumann C, Bandiera S, et al. Clearance of persistent hepatitis C virus infection using a monoclonal antibody specific for thight junction protein claudin-1. Nature Biotechnology. 2015; 33: 549–554.

46. de Jong YP, Dorner M, Mommersteeg MC, Xiao JW, Balazs AB, Robbins JB, Winer BY, Gerges S, Vega K, Labitt RN, Donovan BM, et al. Broadly neutralizing antibodies abrogate established hepatitis C virus infection. Sci Transl Med. 2014; 6 254ra129

47. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, Bismuth H. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med. 1993; 329: 1842–1847. [PubMed: 8247035]

48. Eren R, Ilan E, Nussbaum O, Lubin I, Terkieltaub D, Arazi Y, Ben-Moshe O, Kitchinzky A, Berr S, Gopher J, Zauberman A, et al. Preclinical evaluation of two human antihepatitis B virus (HBV) monoclonal antibodies in the HBV-trimera mouse model and in HBV chronic carrier chimpanzees. Hepatology. 2000; 32: 588–596. [PubMed: 10960454]

49. Galun E, Eren R, Safadi R, Ashour Y, Terrault N, Keeffe EB, Matot E, Mizrachi S, Terkieltaub D, Zohar M, Lubin I, et al. Clinical evaluation (phase I) of a combination of two human monoclonal antibodies to HBV: safety and antiviral properties. Hepatology. 2002; 35: 673–679. [PubMed: 11870383]

50. Zhang TY, Yuan Q, Zhao JH, Zhang YL, Yuan LZ, Lan Y, Lo YC, Sun CP, Wu CR, Zhang JF, Zhang Y, et al. Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen. Gut. 2015.

51. Sureau C. A unique monoclonal antibody for therapeutic use against chronic hepatitis B: not all antibodies are created equal. Gut. 2015.

52. Glebe D, Aliakbari M, Krass P, Knoop EV, Valerius KP, Gerlich WH. Pre-s1 antigen-dependent infection of Tupaia hepatocyte cultures with human hepatitis B virus. J Virol. 2003; 77: 9511–9521. [PubMed: 12915565]

53. Hong HJ, Ryu CJ, Hur H, Kim S, Oh HK, Oh MS, Park SY. In vivo neutralization of hepatitis B virus infection by an anti-preS1 humanized antibody in chimpanzees. Virology. 2004; 318: 134–141. [PubMed: 14972542]

54. Petcu DJ, Aldrich CE, Coates L, Taylor JM, Mason WS. Suramin inhibits in vitro infection by duck hepatitis B virus, Rous sarcoma virus, and hepatitis delta virus. Virology. 1988; 167: 385–392. [PubMed: 2462306]

55. Krepstakies M, Lucifora J, Nagel CH, Zeisel MB, Holstermann B, Hohenberg H, Kowalski I, Gutsmann T, Baumert TF, Brandenburg K, Hauber J, et al. A new class of synthetic peptide inhibitors blocks attachment and entry of human pathogenic viruses. J Infect Dis. 2012; 205: 1654–1664. [PubMed: 22457281]

56. Petersen J, Dandri M, Mier W, Lutgehetmann M, Volz T, von Weizsacker F, Haberkorn U, Fischer L, Pollok JM, Erbes B, Seitz S, et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol. 2008; 26: 335–341. [PubMed: 18297057]

57. Volz T, Allweiss L, ḾBarek MB, Warlich M, Lohse AW, Pollok JM, Alexandrov A, Urban S, Petersen J, Lütgehetmann M, Dandri M. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol. 2013; 58: 861–867. [PubMed: 23246506]

58. Bogomolov P, Voronkova N, Allweiss L, Dandri M, Schwab M, Lempp FA, Haag M, Wedemeyer H, Alexandrov A, Urban S. A proof-of-concept Phase 2a clinical trial with HBV/HDV entry inhibitor Myrcludex B. Hepatology. 2014; 60: 1279a–1280a.

59. Nkongolo S, Ni Y, Lempp FA, Kaufman C, Lindner T, Esser-Nobis K, Lohmann V, Mier W, Mehrle S, Urban S. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor. J Hepatol. 2014; 60: 723–731. [PubMed: 24295872]

60. Lucifora J, Esser K, Protzer U. Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes. Antiviral Res. 2013; 97: 195–197. [PubMed: 23266293]

61. Ko C, Park WJ, Park S, Kim S, Windisch MP, Ryu WS. The FDA approved drug irbesartan inhibits HBV-infection in HepG2 cells stably expressing sodium taurocholate co-transporting polypeptide. Antivir Ther. 2015.

62. Blanchet M, Sureau C, Labonte P. Use of FDA approved therapeutics with hNTCP metabolic inhibitory properties to impair the HDV lifecycle. Antiviral Res. 2014; 106: 111–115. [PubMed: 24717262]

63. Kaneko M, Watashi K, Kamisuki S, Matsunaga H, Iwamoto M, Kawai F, Ohashi H, Tsukuda S, Shimura S, Suzuki R, Aizaki H, et al. A Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting Sodium Taurocholate Cotransporting Polypeptide. J Virol. 2015; 89: 11945–11953. [PubMed: 26378168]

64. Dong Z, Ekins S, Polli JE. Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP). Mol Pharm. 2013; 10: 1008–1019. [PubMed: 23339484]

65. Huang HC, Tao MH, Hung TM, Chen JC, Lin ZJ, Huang C. (-)-Epigallocatechin-3-gallate inhibits entry of hepatitis B virus into hepatocytes. Antiviral Res. 2014; 111: 100–111. [PubMed: 25260897]

66. Nathan C. Fresh approaches to anti-infective therapies. Sci Transl Med. 2012; 4 140sr142

67. Belloni L, Allweiss L, Guerrieri F, Pediconi N, Volz T, Pollicino T, Petersen J, Raimondo G, Dandri M, Levrero M. IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest. 2012; 122: 529–537. [PubMed: 22251702]

68. Liu F, Campagna M, Qi Y, Zhao X, Guo F, Xu C, Li S, Li W, Block TM, Chang J, Guo JT. Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes. PLoS Pathog. 2013; 9 e1003613 [PubMed: 24068929]

Figure 1. Molecular mechanisms of HBV entry and entry inhibitors.
HBV viral particles first interact with hepatic HSPGs, including GPC5. This interaction is inhibited by a monoclonal anti-GPC5 antibody or heparinase treatment. HBV then binds directly to NTCP at the bile acid pocket site. Several NTCP inhibitors block this interaction and prevent HBV entry,such as cyclosporin A, ezetimibe, irbesartan, vanitaracin A, ritonavir or epigallocatechin gallate. A synthetic HBV-derived preS1 peptide (Myrcludex B) exhibits a strong antiviral activity by competing with HBV for NTCP binding. After binding to NTCP, the virus is internalized but the underlying mechanisms are still unknown.

Table 1

Examples of HBV entry inhibitors targeting NTCP in hepatocytes

Name	Class	Development stage	References
Myrcludex B	Myristoylated lipopeptide	Clinical phase II	[57]
Cyclosporin A	Immunosuppressant	Cell culture	[44, 59]
Ezetimibe	b-lactam	Cell culture	[60]
Irbesartan	Angiotensin receptor blocker	Cell culture	[61, 62]
Vanitaracin A	Fungal tricyclic polyketide	Cell culture	[63]
Ritonavir	HIV protease inhibitor	Cell culture	[62]
Epigallocatechin gallate	Green tea polyphenol	Cell culture	[65]